INHIBITION OF PCSK9 AFFECTS SERUM LIPOPROTEIN FUNCTIONS IN PATIENTS WITH FAMILIAL HYPERCHOLESTEROLEMIA

被引：0
|
作者：
Palumbo, M. [1 ]
Adorni, M. P. [2 ]
Zimetti, F. [1 ]
Pavanello, C. [3 ]
Giammanco, A. [4 ]
Cefalu, A. B. [4 ]
Noto, D. [4 ]
Piro, S. [5 ]
Di Pino, A. [5 ]
Averna, M. [4 ]
Calabresi, L. [3 ]
Bernini, F. [1 ]
Purrello, F. [5 ]
Scicali, R. [5 ]
机构：
[1] Univ Parma, Dept Food & Drug, Parma, Italy
[2] Univ Parma, Dept Med & Surg, Unit Neurosci, Parma, Italy
[3] Univ Milan, Pharmacol & Biomol Sci, Milan, Italy
[4] Univ Palermo, Dept Hlth Promot Mother & Child Care Internal Med, Palermo, Italy
[5] ARNAS GARIBALDI NESIMA, Dept Med, Catania, Italy
来源：
ATHEROSCLEROSIS | 2022年 / 355卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
EP222
引用
收藏
页码：E157 / E157
页数：1
相关论文
共 50 条
  • [41] Screening of PCSK9 and LDLR genetic variants in Familial Hypercholesterolemia (FH) patients in India
    Reddy, Lakshmi Lavanya
    Shah, Swarup A. V.
    Ponde, Chandrashekhar K.
    Dalal, Jamshed J.
    Jatale, Raj G.
    Dalal, Reeta J.
    Rajani, Rajesh M.
    Pillai, Sudhir K.
    Vanjani, Chander V.
    Ashavaid, Tester F.
    JOURNAL OF HUMAN GENETICS, 2021, 66 (10) : 983 - 993
  • [42] PCSK9 Inhibition: Does Lipoprotein Size Matter?
    Si-Tayeb, Karim
    Cariou, Bertrand
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2015, 4 (11):
  • [43] Role of PCSK9 Inhibitors in High Risk Patients with Dyslipidemia: Focus on Familial Hypercholesterolemia
    Papademetriou, Vasilios
    Stavropoulos, Konstantinos
    Papadopoulos, Christodoulos
    Koutsampasopoulos, Konstantinos
    Dimitriadis, Kiriakos
    Tsioufis, Kostas
    CURRENT PHARMACEUTICAL DESIGN, 2018, 24 (31) : 3347 - 3653
  • [44] Impact of LDLR and PCSK9 pathogenic variants in Japanese heterozygous familial hypercholesterolemia patients
    Hori, Mika
    Ohta, Naotaka
    Takahashi, Atsushi
    Masuda, Hiroaki
    Isoda, Rieko
    Yamamoto, Suguru
    Son, Cheol
    Ogura, Masatsune
    Hosoda, Kiminori
    Miyamoto, Yoshihiro
    Harada-Shiba, Mariko
    ATHEROSCLEROSIS, 2019, 289 : 101 - 108
  • [45] Screening of PCSK9 and LDLR genetic variants in Familial Hypercholesterolemia (FH) patients in India
    Lakshmi Lavanya Reddy
    Swarup A. V. Shah
    Chandrashekhar K. Ponde
    Jamshed J. Dalal
    Raj G. Jatale
    Reeta J. Dalal
    Rajesh M. Rajani
    Sudhir K. Pillai
    Chander V. Vanjani
    Tester F. Ashavaid
    Journal of Human Genetics, 2021, 66 : 983 - 993
  • [46] Lipoprotein(a) in Familial Hypercholesterolemia With Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Gain-of-Function Mutations
    Tada, Hayato
    Kawashiri, Masa-aki
    Yoshida, Taiji
    Teramoto, Ryota
    Nohara, Atsushi
    Konno, Tetsuo
    Inazu, Akihiro
    Mabuchi, Hiroshi
    Yamagishi, Masakazu
    Hayashi, Kenshi
    CIRCULATION JOURNAL, 2016, 80 (02) : 512 - +
  • [47] PCSK9 Inhibition With Monoclonal Antibodies: Modern Management of Hypercholesterolemia
    Ito, Matthew K.
    Santos, Raul D.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2017, 57 (01): : 7 - 32
  • [48] PCSK9 inhibition for the treatment of hypercholesterolemia: Promises and emerging challenges
    Norata, Giuseppe Danilo
    Tibolla, Gianpaolo
    Catapano, Alberico Luigi
    VASCULAR PHARMACOLOGY, 2014, 62 (02) : 103 - 111
  • [49] PCSK9 Mutations in Familial Hypercholesterolemia: from a Groundbreaking Discovery to Anti-PCSK9 Therapies
    El Khoury, Petra
    Elbitar, Sandy
    Ghaleb, Youmna
    Abou Khalil, Yara
    Varret, Mathilde
    Boileau, Catherine
    Abifadel, Marianne
    CURRENT ATHEROSCLEROSIS REPORTS, 2017, 19 (12)
  • [50] PCSK9 Mutations in Familial Hypercholesterolemia: from a Groundbreaking Discovery to Anti-PCSK9 Therapies
    Petra El Khoury
    Sandy Elbitar
    Youmna Ghaleb
    Yara Abou Khalil
    Mathilde Varret
    Catherine Boileau
    Marianne Abifadel
    Current Atherosclerosis Reports, 2017, 19
12345